Emyria Ltd · ASX:EMD
Emyria — Q3 2026 Earnings Presentation
11 slides from Emyria's earnings presentation, Nov 2, 2026
Slide 1: Quarterly Update for the period ended 30 September
ASX : EMD Quarterly Update for the period ended 30 September Quarterly Webinar 1 Advanced therapies. Compassionate care.
Slide 2: Important notice and disclaimer
Important notice and disclaimer Important notice and disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to presentation is not a financial p
Slide 3: Who are we?
Who are we? Brisbane Clinics across four states 5 ASX: EMD Treatment beds Building a National network of specialty 18 mental health clinics Treating PTSD and treatment- Clinician Workforce resistant depression (APs+therapists) ~145 Patients treated Sydney >160 Perth (x2) Mornington FY26 revenue, up
Slide 4: Worldwide first mover advantage
Worldwide first mover advantage A Regulated Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions MDMA-assisted therapy This regulation change has Australia created a For PTSD is the FIRST jurisdiction in Significant the world to reschedule Market two promisin
Slide 5: Major Funders are Spending Millions Annually
Major Funders are Spending Millions Annually Reimbursement has commenced for Psychedelic Assisted Therapy Private Department of Other Health Insurers Veterans’ Affairs Insurers Life insurers paid out more $2B ($219M/yr in 2024 alone) 1 The Government spends than Spent by Medibank on mental health ho
Slide 6: Patient journey | Treatment model + bed capacity
Patient journey I Treatment model + bed capacity Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up ACTIVE TREATMENT PROTOCOL BED CAPACITY Dosing Dosing Clinic Beds days / SCREENING Day 3 week Dosing Dosing AND Day 1 Day 2 (8 hrs) FOLLOW-UP PREPARATION (8 hrs) (8 hrs) Perth (x2)
Slide 7: Maturing clinic | Perth Clinic dosing days May 2025 to June 2026
Maturing clinic I Perth Clinic dosing days May 2025 to June 2026 Clinic Capacity 80 dosing days / month 31 Seasonal Impact –Easter Seasonal Impact - Christmas SOURCES: 1. See ASX announcement 11 June 2026 * Monthly stand alone clinic breakeven. 7 Advanced therapies. Compassionate care.
Slide 8: Quarterly Highlights
Quarterly Highlights This quarter has seen major developments for EMD Opening of first Unlocked clinician Appointment of Presentation at FDA Sydney Clinic capacity Strategic Advisor Hearing NSW clinic opened in September 2026, Additional Authorised Prescriber Former US Secretary of Veterans Affairs
Slide 9: Momentum in Psychedelic Medicine Sector Continues to Build
Momentum in Psychedelic Medicine Sector Continues to Build Recent macro catalysts provide significant tailwinds for Emyria A new era is unfolding in psychedelic medicine – first-mover Emyria is well positioned to take advantage of the opportunities that are arising 9 Advanced therapies. Compassionat
Slide 10: Emyria | Looking Ahead
Emyria | Looking Ahead Delivering on commitments to shareholders Core focus areas: • Starting first DVA-funded treatments for veterans • Pursuing US commercial and partnership opportunities supported by Strategic Advisor Dr David Shulkin • Growing referrer education and increasing use of Empax netwo
Slide 11: Investor Q+A
Investor Q+A Greg Hutchinson [email protected] Mary-Ann Rennie [email protected] Visit Our Investor / Investor Hub Media Inquiries [email protected]